Metrics to compare | CESSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCESSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.8x | 9.1x | −0.4x | |
PEG Ratio | −0.85 | −0.40 | 0.00 | |
Price/Book | 40.0x | 1.8x | 2.6x | |
Price / LTM Sales | 80.9x | 1.1x | 3.0x | |
Upside (Analyst Target) | - | 20.6% | 49.1% | |
Fair Value Upside | Unlock | 14.2% | 6.3% | Unlock |
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children. Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.